医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

JAKARTA, Indonesia

Meiji Seika Pharma Co., Ltd. “Meiji” has announced that PT Meiji Indonesian Pharmaceutical Industries “PT Meiji”, affiliated Indonesian subsidiary of Meiji, has launched today “Meiact MS Fine Granules 10%” (Cefditoren Pivoxil), an oral cephem antibiotic for children.

Since Meiji started its marketing activities for Meiact within Japan in 1994, it is used as a cephem antibiotic to treat a wide range of infectious diseases. Meiact has already been approved in 27 countries and regions and is used around the world.

PT. Meiji has been marketing Meiact tablets in Indonesia since 2004. By adding Meiact MS Fine Granules 10%, we believe we can make further contributions to the treatment of pediatric infectious diseases in Indonesia. In the future, PT. Meiji will conduct promotional activities mainly at PT Meiji’s 21 marketing representative offices in Indonesia.

Through PT. Meiji, Meiji will contribute to improve quality of life in Indonesia as a leading company in the treatment of infectious diseases in Asia.

About Meiji Seika Pharma Co., Ltd
Address: Chuo-ku, Tokyo Japan
President Director: Daikichiro Kobayashi
https://www.meiji.com/global/about-us/corporate-profile/meiji-seika-pharma/

About PT. Meiji Indonesian Pharmaceutical Industries
Established: 1974
Address: Jalan Prof. Dr. Soepomo No. 40, Tebet, Jakarta Selatan, 12870 Indonesia
President Director: Masanobu Sato
Employees: 799, as of March, 2019
Parent Company: Meiji Seika Pharma Co., Ltd.

Scope of Business: Manufacture, sales, and export of medical materials
https://meiji.co.id/id

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190731005425/en/